Biogen (BIIB)
| Company | Ticker | Sector | Industry | Quality | PAR |
|---|---|---|---|---|
| Biogen | BIIB | Healthcare | Drug Manufacturers - General | 27 | -6.0% |
| Current Price (11/16) | $300.01 | |||
| CAPS Rating (Rate this stock on CAPS) |  |
|||
| Expected Income Statement | ||||
| Current Sales | 10,363.2 | |||
| Sales Growth Forecast | -3.8% | |||
| Net Profit Margin | 16.0% | |||
| Projected Shares Outstanding | 129.96 | |||
| EPS - Five year Forecast | $10.49 | |||
| Average P/E Ratio | 21.0 | |||
| Projected Average Price | $220.24 | |||
| Price Appreciation (Annualized) | -6.0% | |||
| Annual Dividend Yield | 0.0% | |||
| Projected Annual Return | -6.0% | |||
| Quality | ||||
| Financial Strength | 88 | 22.1 | ||
| EPS Stability | 41 | 10.2 | ||
| Industry Sales Growth Rate | 4.0% | -12.0 | ||
| Industry Net Profit Margin | 19.3% | 10.4 | ||
| Calculated Quality Rating | 30.6 | |||
| Fool CAPS | ||||
Total Players
955
Outperforms
79
Underperforms
All-Stars (230)
215
Outperforms (93%)
15
Underperforms
|
||||
| Fundamental Data Updated: 09/30/2022 | ||||